---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-083961"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2026-07-31T20:06:04+00:00"
generated_at: "2026-07-31T20:07:22.168149+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INmune Bio receives ~$4.6M in R&D rebates from Australia and UK, extends cash runway

## Summary
- Received ~$4.2M R&D cash rebate from Australia on July 30, 2026, plus ~$0.4M from UK in June 2026.
- Combined ~$4.6M in non-dilutive rebates exceeded net cash used in Q2 operating activities (after adjusting for UK rebate).
- Strengthens balance sheet and extends cash runway without issuing additional equity.
- Rebates support advancement of CORDStrom toward regulatory filings (MAA UK MHRA 2026, EU EMA 2027, US BLA).

## SEC filing metadata
- accession: 0001213900-26-083961
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2026-07-31T20:06:04+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390026083961/0001213900-26-083961-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390026083961/ea0300069-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-083961
- JSON: https://secwatch.observer/filing/0001213900-26-083961.json
- Plain text: https://secwatch.observer/filing/0001213900-26-083961.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.